Performance of the Hepatic Encephalopathy Scoring Algorithm in a Clinical Trial of Patients With Cirrhosis and Severe Hepatic Encephalopathy

Hassanein, Tarek; Blei, Andres T.; Perry, William; Hilsabeck, Robin; Stange, Jan; Larsen, Fin S.; Brown, Robert S.; Caldwell, Stephen; McGuire, Brendan; Nevens, Frederik; Fontana, Robert
June 2009
American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1392
Academic Journal
OBJECTIVES:The grading of hepatic encephalopathy (HE) is based on a combination of indicators that reflect the state of consciousness, intellectual function, changes in behavior, and neuromuscular alterations seen in patients with liver failure.METHODS:We modified the traditional West Haven criteria (WHC) to provide an objective assessment of the cognitive parameters to complement the subjective clinical ratings for the performance of extracorporeal albumin dialysis (ECAD) using a molecular adsorption recirculating system in patients with cirrhosis and severe (grade III/IV) encephalopathy. The HE Scoring Algorithm (HESA) combined clinical indicators with those derived from simple neuropsychological tests, the latter more often used in milder grades of HE (I/II). The performance of each indicator was compared across grades and sites.RESULTS:Results of HESA were also compared with the Glasgow Coma Scale. A total of 597 evaluations were performed in patients randomized to ECAD plus standard medical therapy or the latter only. Most parameters exhibited significant separation between grades; the most effective indicators were lack of verbal, eye, and motor response (grade IV), somnolence and disorientation to place (grade III), and lethargy and disorientation to time (grade II). Two clinical and four neuropsychological indicators were useful to classify patients as grade I. The Glasgow Coma Scale differed among the four stages of the WHC, but the differences between grades I and II were small and not clinically useful.CONCLUSION:HESA extends the traditional WHC for grading HE. In the absence of a “gold” standard, the most useful indicators noted in this trial should be further validated.Am J Gastroenterol 2009; 104:1392–1400; doi:10.1038/ajg.2009.160; published online 19 May 2009


Related Articles

  • Hyperion Therapeutics' Glycerol Phenylbutyrate Meets Primary Endpoint in Phase II Study in Episodic Hepatic Encephalopathy.  // Biomedical Market Newsletter;6/7/2012, Vol. 21, p1 

    The article informs that Hyperion Therapeutics Inc.'s phase II study of glycerol phenylbutyrate, an investigational drug for the treatment of episodic hepatic encephalopathy (HE) has met its primary endpoint. The results from the study showed that the proportion of patients experiencing at least...

  • The Relative Contribution of Hepatic Encephalopathy to Burden in Patients With Cirrhosis. Parikh, Neehar; Butt, Zeeshan // American Journal of Gastroenterology;Mar2012, Vol. 107 Issue 3, p486 

    A letter to the editor is presented in response to the article "The multidimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers," by J. S. Bajaj and colleagues in the 2011 issue.

  • Bromocriptine-associated hyponatraemia in cirrhosis.  // British Medical Journal (Clinical Research Edition);11/27/1982, Vol. 285 Issue 6354, p1534 

    Presents cases of patients with bromocriptine-associated hyponatraemia in cirrhosis. Use of bromocriptine in treating chronic portosystemic encephalopathy; Features of patients with cirrhosis; Evaluation of the mechanism of bromocriptine among various patients.

  • Dietary management of hepatic encephalopathy. Seymour, Carol A // BMJ: British Medical Journal (International Edition);05/22/99, Vol. 318 Issue 7195, p1364 

    Discusses the dietary management of hepatic encephalopathy among patients with cirrhosis. Definition of hepatic encephalopathy; Information on the dietary restrictions for the patients; Problems of physicians regarding dietary restrictions; Findings on the ideal dietary intakes of the patients.

  • Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis. Guevara, Mónica; Baccaro, M. E.; Torre, Aldo; Gómez-Ansón, Beatriz; Ríos, José; Torres, Ferrán; Rami, Lorena; Monté-Rubio, Gemma C.; Martín-Llahí, Marta; Arroyo, Vicente; Ginès, Pere // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1382 

    OBJECTIVES:The aim of this study was to investigate whether hyponatremia is a risk factor of overt hepatic encephalopathy (HE) in cirrhosis.METHODS:A total of 61 patients with cirrhosis were evaluated prospectively for 1 year and all episodes of overt HE were recorded. Predictive factors of HE...

  • Editorial: Hyponatremia in Hepatic Encephalopathy:An Accomplice or Innocent Bystander? Byung Cheol Yun; Kim, W. Ray // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1390 

    Hyponatremia, a common complication in patients with advanced liver disease and impaired free water clearance, has been shown to be an important predictor of short-term mortality. Hepatic encephalopathy, also a late complication of end-stage liver disease, has been associated with low-grade...

  • Persistence of Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy. Umapathy, Sridharan; Dhiman, Radha K; Grover, Sandeep; Duseja, Ajay; Chawla, Yogesh K // American Journal of Gastroenterology;Jul2014, Vol. 109 Issue 7, p1011 

    OBJECTIVES:Hepatic encephalopathy (HE) represents a spectrum of neurocognitive impairment seen in cirrhotic patients and is considered to be fully reversible with treatment; however, recent evidence suggests otherwise. This longitudinal study was carried out to evaluate the persistence of...

  • Higher Grades and Repeated Recurrence of Hepatic Encephalopathy May Be Related to High Serum Manganese Levels. Kobtan, Abdelrahman; El-Kalla, Ferial; Soliman, Hanan; Zakaria, Soha; Goda, Mohamed // Biological Trace Element Research;Feb2016, Vol. 169 Issue 2, p153 

    Hepatic encephalopathy is a serious complication of liver failure. Until now, the precise pathophysiologic mechanisms are not fully determined. It has been demonstrated that manganese plays an important role in the pathogenesis of hepatic encephalopathy. Therefore, we studied manganese levels in...

  • The "unphysiology" of dialysis: A major cause of dialysis side effects? Kjellstrand, Carl M.; Evans, Robert L.; Petersen, Robert J.; Shideman, Jeffrey R.; von Hartitzsch, Barry; Buselmeier, Theodore J. // Kidney International Supplement;Jan1975, Issue 2, pS-30 

    This article presents information on unphysiology being a major side effect of dialysis. Studies attempting to relate the side effects of hemodialysis to predialysis plasma toxin concentrations have been largely inconclusive. However, side effects have been elicited only at blood concentrations...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics